Lebovits Chaim's Form 4 filing
Brainstorm Cell Therapeutics Inc. (BCLI) · filed May 23, 2024
- Accession no.
- 0001104659-24-064415
- Filed
- May 23, 2024
- Trade date
- May 21-22, 2024
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions. It was filed 2 days after the trade.
This filing was later replaced by the amendment 0001104659-24-084343 (Jul 31, 2024). Trade tables on this site use the amended version.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Lebovits ChaimCIK 0001406302 | Officer (President & CEO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| May 21, 2024 | Common Stock | AGrant or awardAcquired | +25,000 | $0.58 | +$14,500 | 1,124,865 | Direct | |
| May 22, 2024 | Common Stock | AGrant or awardAcquired | +25,000 | $0.64 | +$16,000 | 1,149,865 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.